Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Clinical trial NCT01602952 · COMPLETED

Trial details

NCT number: NCT01602952
Sponsor: Il-Yang Pharm. Co., Ltd.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Philadelphia Chromosome Hematologic Diseases

Start date: 2008-07-01
Primary completion: 2012-10-01
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.